文献速递心脑血管急症消化、代谢与肾脏急症

急性缺血性卒中中间歇性与持续输注降压药比较

Comparison of intermittent versus continuous infusion antihypertensives in acute ischemic stroke.
PubMed 文献 · Am J Emerg Med · 2021-11-29
一句话结论急性缺血性卒中需静脉降压者,间歇与持续输注降压药在就诊至阿替普酶时间上无显著差异(53 vs 57分钟,p=0.17)。

这项多中心回顾性队列研究纳入2013年9月1日至2020年8月31日急诊就诊、接受阿替普酶且需静脉降压的急性缺血性卒中患者,比较间歇(拉贝洛尔或肼屈嗪)与持续输注(尼卡地平或氯维地平)降压策略对就诊至给药时间的影响。结果显示间歇组122例中位53分钟、持续组57例57分钟(p=0.17),15分钟内达血压目标<185/110 mmHg比例及不良事件发生率两组相似。成本上间歇组2.20美元低于持续组71.40美元。提示初始降压方式选择未显著影响溶栓时效。

要点

  • 急性缺血性卒中需静脉降压者,间歇组(122例)中位就诊至阿替普酶时间53分钟,持续输注组(57例)57分钟,p=0.17。
  • 初始降压后15分钟内血压达标(<185/110 mmHg)比例及不良事件发生率两组相似。
  • 成本分析:间歇性降压药2.20美元,持续输注降压药71.40美元,间歇组更低。
  • 研究为多中心回顾性队列,纳入标准包括急诊就诊、接受阿替普酶且需静脉降压的成人患者。

适用人群与场景

  • 年龄≥18岁、2013年9月1日至2020年8月31日急诊就诊、接受阿替普酶治疗急性缺血性卒中、且需静脉降压药控制血压的患者。
  • 排除:初始使用非研究降压药;初始研究降压药在阿替普酶前>2小时或之后任何时间给药;阿替普酶前同时接受间歇和持续输注降压药。

诊断标准与关键阈值

  • 血压目标:<185/110 mmHg。

处置流程与药物剂量

  • 间歇降压策略:拉贝洛尔或肼屈嗪。
  • 持续输注降压策略:尼卡地平或氯维地平。

研究设计与关键结果

  • 多中心回顾性队列研究,纳入122例接受间歇降压药和57例接受持续输注降压药的患者。
  • 主要终点就诊至阿替普酶时间:间歇组中位53分钟 vs 持续组57分钟(p=0.17),无显著差异。
  • 次要终点:初始降压后15分钟内血压达标(<185/110 mmHg)比例及不良事件发生率两组相似。
  • 成本分析:间歇性降压药2.20美元 vs 持续输注降压药71.40美元,间歇组更低。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于急性缺血性卒中需静脉降压且计划接受阿替普酶的患者,初始选择间歇(拉贝洛尔或肼屈嗪)或持续输注(尼卡地平或氯维地平)降压未显著影响就诊至给药时间(53 vs 57分钟,p=0.17)。
  • 间歇性降压药成本低于持续输注降压药(2.20 vs 71.40美元)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The optimal approach to blood pressure (BP) management in acute ischemic stroke remains unclear. The purpose of this study was to determine if an intermittent (labetalol or hydralazine) or continuous infusion (nicardipine or clevidipine) antihypertensive strategy facilitated timelier alteplase administration.

METHODS: Patients ≥18 years who presented to the emergency department (ED) between September 1, 2013 and August 31, 2020, received alteplase for acute ischemic stroke, and required BP management with an intravenous antihypertensive were included in this multicenter, retrospective cohort study. Exclusion criteria were initial administration of a non-study antihypertensive, initial study antihypertensive administration >2 hours prior to or any time following alteplase, or receipt of both an intermittent and continuous infusion antihypertensive prior to alteplase. The primary endpoint was the time from ED presentation to alteplase administration.

RESULTS: During the study period, 122 patients received an intermittent antihypertensive and 57 patients received a continuous infusion antihypertensive. The median door-to-needle time was 53 minutes for patients who received an intermittent antihypertensive compared to 57 minutes for those who received a continuous infusion antihypertensive (p=0.17). Secondarily, the proportion of patients who achieved the BP target <185/110 mmHg within 15 minutes of initial antihypertensive administration and the incidence of adverse events were similar between treatment groups. In cost analysis, intermittent antihypertensives were less expensive than continuous infusion antihypertensives ($2.20 vs. $71.40).

CONCLUSIONS: Among patients with acute ischemic stroke and uncontrolled BP, the initial use of an intermittent or continuous infusion antihypertensive did not significantly impact the time to alteplase administration.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Kamp A, Huang W, Lassiter T, et al. Comparison of intermittent versus continuous infusion antihypertensives in acute ischemic stroke. Am J Emerg Med. 2021. PMID: 34959025. doi:10.1016/j.ajem.2021.11.037

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。